ArticleBMC endocrine disorders2025
Atypical presentation of pseudohypoparathyroidism with absence of mutations in the GNAS gene: a case report.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis case report aimed to broaden the understanding of pseudohypoparathyroidism (PHP) manifestations when typical mutations in the GNAS gene are absent. The clinical, biochemical, and genetic investigations of a PHP case revealed diagnostic challenges and emphasized the importance of comprehensive genetic analysis for early diagnosis and appropriate management, as well as improved patient outcomes. CASE PRESENTATION: The case involved a 21-year-old man who has experienced recurrent limb convulsions and episodes of altered consciousness since the age of eight. Recent assessments during frequent hospitalization uncovered findings consistent with PHP, including hypocalcemia, hyperphosphatemia, elevated parathyroid hormone level, and short stature. Notably, genetic testing did not reveal mutations in the GNAS gene, which could be typically associated with PHP. Diagnostic tests revealed mild abnormalities in the electroencephalogram and multiple abnormal signals in brain magnetic resonance imaging, specifically in the caudate, lenticular, dentate, and thalamus nuclei. Cranial computed tomography scan confirmed symmetrical calcifications in the basal ganglia. Biochemical analysis revealed severely altered calcium and phosphorus metabolism. Routine endocrine and neurological evaluations yielded results within normal ranges. Genetic testing identified a novel missense mutation in the GHSR gene, which has not been reported in the database and may reasonably explain some of the patient's phenotypic features.
conclusionsWhile mutations in the GNAS gene are the primary genetic markers for PHP, the presence of other genetic mutations in some cases complicates the clinical analysis. This case highlights the need for a comprehensive genetic screening approach in patients with PHP-like symptoms who do not exhibit mutations in the GNAS gene, to avoid misdiagnosis and ensure timely intervention. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.